A multicenter, randomized phase II trial named DURABLE reported results suggesting a maintenance regimen of durvalumab plus anlotinib outperformed durvalumab monotherapy in extensive-stage small-cell lung cancer (ES-SCLC). The study evaluated efficacy and biomarker profiles across both strategies, with maintenance framed as the key differentiator. The excerpt does not provide numerical hazard ratios or response rates, but it highlights the direction of benefit favoring the combination for ongoing management after initial therapy. For ES-SCLC—an area with limited durable options—any maintenance advantage can reshape sequencing decisions. Biomarker analyses were also described as part of the dataset, indicating the trial was designed to test both clinical impact and patient stratification signals.